Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fate Therapeutics (NQ: FATE )

2.430 +0.060 (+2.53%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,812,152
Open 2.420
Bid (Size) 2.370 (1)
Ask (Size) 2.460 (43)
Prev. Close 2.370
Today's Range 2.320 - 2.481
52wk Range 1.910 - 8.830
Shares Outstanding 98,384,456
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
From Fate Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-34.15%
-34.15%
1 Month
-22.12%
-22.12%
3 Month
-42.00%
-42.00%
6 Month
-42.42%
-42.42%
1 Year
+1.67%
+1.67%

More News

Read More
FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts
Via Benzinga
Forecasting The Future: 8 Analyst Projections For Fate Therapeutics
Via Benzinga
Where Fate Therapeutics Stands With Analysts
Via Benzinga
Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors
From Fate Therapeutics, Inc.
Via GlobeNewswire
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
Via The Motley Fool
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
From Fate Therapeutics, Inc.
Via GlobeNewswire
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
From Fate Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.